奥锐特 (605116)
Aurisco Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data available
Company NameAoruite Pharmaceutical Co., Ltd.
Listing Date2020-09-21
Issue Price8.37RMB
Registered Capital40618.323410k RMB
Legal RepresentativePeng Zhien
Registered AddressBadu Industrial Park, Tiantai County, Zhejiang Province
IndustryChemical Pharmaceuticals
Main BusinessPrimarily engaged in the research and development, production, and sales of specialty active pharmaceutical ingredients (APIs) and pharmaceutical intermediates.
Company ProfileAoruite Pharmaceutical Co., Ltd. was founded in 1998. The company's main business is the research and development, production, and sales of specialty intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. It is a pharmaceutical enterprise integrating scientific research, production, and sales.
The company is committed to providing high-quality pharmaceutical chemicals and contract manufacturing services to global pharmaceutical companies.
The company's headquarters is located in Tiantai County, Zhejiang Province, with subsidiaries in Shanghai and Yangzhou.
Aoruite Pharmaceutical Co., Ltd. consistently strengthens its technological innovation system, prioritizing scientific and technological innovation. It utilizes advanced and complete production facilities and a comprehensive quality assurance system to ensure the safe production of high-quality products.
Proactive and innovative thinking, dedicated and committed employees, and rational resource allocation are the cornerstones that have enabled Aoruite's gradual growth and expansion.
Stock Details
1. Key Indicators
- Total Shares(W): 40619.52
- Circulating A-Shares(W): 40618.32
- Earnings Per Share(RMB): 0.8700
- Net Assets Per Share(RMB): 6.2093
- Operating Revenue(W RMB): 123705.26
- Total Profit(W RMB): 40407.66
- **Net Profit Attributable to Parent(W RMB) **: 35354.06
- Net Profit Growth Rate(%): 24.58
- Weighted Return on Equity(%): 14.3700
- Operating Cash Flow Per Share(RMB): 0.8650
- Undistributed Profit Per Share(RMB): 3.3456
- Capital Reserve Per Share(RMB): 1.5107
2. Main Business
The main business covers:
- Research, development, production and sales of specialty APIs and pharmaceutical intermediates
3. Company Basic Information
- Company Name: Aurisco Pharmaceutical Co., Ltd.
- Listing Date: 2020-09-21
- Industry: Pharmaceutical Manufacturing
- Address: Badu Industrial Park, Tiantai County, Zhejiang Province
- Website: https://www.aurisco.com/
- Company Profile: On May 16, 2017, according to the resolution of Aurisco Limited's shareholders' meeting, Aurisco Limited was converted into a joint stock company through overall change, using the audited net assets of RMB 601,764,333.25 after deducting the safety production reserve as of March 31, 2017. RMB 360,000,000.00 was converted into share capital, and the remaining RMB 241,764,333.25 was recorded as capital reserve. On June 1, 2017, Tianjian Certified Public Accountants verified the receipt of registered capital during this overall change and establishment, and issued the "Capital Verification Report" (Tianjian Yan [2017] No. 207). On June 29, 2017, the company completed the industrial and commercial change registration procedures and obtained the business license issued by the Taizhou Market Supervision Administration.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Zhejiang Tongben Investment Co., Ltd. | Corporate Entity | 15358.32 | 38.00 |
| 2 | Tiantai Borong Investment Partnership (Limited Partnership) | Corporate Entity | 773.06 | 1.91 |
| 3 | Tiantai Boen Investment Management Partnership (Limited Partnership) | Corporate Entity | 660.60 | 1.63 |
| 4 | Guoshou Anbao Health Science Hybrid Securities Investment Fund Class A | Fund | 21.00 | 0.05 |
5. Concept Sectors
- Convertible Bonds
- Quantum Technology
- Generic Drugs
- CXO Concept
- Assisted Reproduction
- Hepatitis Concept
- Innovative Drugs
- Weight Loss Drugs
- Synthetic Biology
- High-Performing Stocks
- Share Buyback Plan
- Proposed Reduction
- Overseas Business
Remarks
- Data update date: 2025-11-07
- Data source: Public Market Information